89zr-tlx250
Recombinant proteinexperimentalImaging agent
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 21, 2021 (NCT04758780)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 89-zirconium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06750419 | Phase 3 | Nov 6, 2024 | Telix |
| NCT04897763 | Early Phase 1 (Phase 1) | Oct 1, 2021 | Aton, Institut de Cancerologie de l'Ouest Paul Papin |
| NCT04758780 | Phase 2 | Sep 21, 2021 | Institut de Cancerologie de l'Ouest Paul Papin, SIRIC ILIAD, Telix |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institut de Cancerologie de l'Ouest Paul Papin | Academic/Hospital | 2 | 2 | 2 | 2021 |
| Telix | For profit | 2 | 1 | 2 | 2021 |
| Aton | For profit | 1 | 0 | 1 | 2021 |
| SIRIC ILIAD | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1